Immuron Ltd SEC Filings

Immuron Limited furnished a Form 6-K announcing that it published two announcements to the Australian Securities Exchange on October 17, 2025. The filing attaches these ASX items and highlights an exhibit titled “Proposed issue of securities - IMC.”

The company states this 6-K, including the exhibit, is furnished and not deemed filed under the Exchange Act, and will not be incorporated by reference into Securities Act filings unless specifically referenced.

Immuron Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish investors with information already released on the Australian Securities Exchange. The filing attaches an ASX announcement as Exhibit 99.1 titled “Immuron Q1 FY26 YoY growth.”

The 6-K itself does not detail the underlying quarterly figures, but signals that Immuron has reported year-over-year growth for the first quarter of fiscal 2026 in its home market disclosure. The company also clarifies that this furnished material is not automatically incorporated into other U.S. securities law filings unless specifically referenced.

Immuron Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with access to materials it released on the Australian Securities Exchange. The company furnished a Public Notice dated October 10, 2025 titled “Notice of Annual General Meeting and Proxy Form.” This document relates to the upcoming annual shareholder meeting and the associated voting materials.

The Notice of Annual General Meeting and Proxy Form is attached as Exhibit 99.1. The submission is designated as furnished, not filed, under U.S. securities laws, meaning it will not automatically be incorporated into other securities law filings unless specifically referenced.

Immuron Limited furnished a Form 6-K for October 2025 to provide U.S. investors with information it released in Australia. The company explains that it published public notices to the Australian Securities Exchange on October 10, 2025 and is attaching one of these as an exhibit.

The attached Exhibit 99.1 is titled “Immuron Submits -529 IND to FDA,” indicating that Immuron has submitted a -529 IND to the U.S. Food and Drug Administration. The company also clarifies that this Form 6-K, including the exhibit, is being furnished rather than filed and will only be incorporated into other U.S. securities filings if specifically referenced.

Immuron Limited is offering up to $2,847,954 of American Depositary Shares (ADSs) representing its ordinary shares through an at-the-market program under its Form F-3. The company may sell ADSs from time to time via H.C. Wainwright & Co., which will act as sales agent or principal and receive a 3.0% cash commission on gross sales. Each ADS represents 40 ordinary shares, and the ADSs trade on Nasdaq under the symbol IMRN, while the ordinary shares trade on the ASX under IMC. The capacity reflects Form F-3 General Instruction I.B.5 limits based on a public float of approximately $14,908,499, with about $2,068,866 already sold in the past 12 months, allowing up to an additional $2,847,954 of securities to be issued under this program.

Immuron Limited is updating its at-the-market share sale program with H.C. Wainwright & Co., increasing the additional aggregate offering capacity by $2,847,954 of American Depositary Shares under their existing At The Market Offering Agreement. These ADSs will be issued under Immuron’s effective shelf registration statement on Form F-3 and related prospectus, as supplemented by a new prospectus supplement dated October 3, 2025. The company also files a legal opinion covering $2,607,382 of securities issuable under the agreement and clarifies that this 6-K is incorporated by reference into the registration statement.

Immuron Limited submitted a Form 6-K as a foreign private issuer to furnish information previously published to the Australian Securities Exchange. The filing primarily forwards a publicly released letter to shareholders, which is included as Exhibit 99.1. The company specifies that this Form 6-K, including its exhibit, is furnished rather than filed under U.S. securities laws and will only be incorporated into other U.S. filings if explicitly referenced.

Immuron Limited submitted a Form 6-K to provide an updated consent from its independent registered public accounting firm, Grant Thornton Audit Pty Ltd, dated September 30, 2025. This consent allows Grant Thornton’s audit work and reports to be used in connection with Immuron’s existing shelf registration statement on Form F-3 (File No. 333-280667).

The consent is filed as Exhibit 23.1 and is expressly incorporated by reference into the Form F-3 from the date this report is submitted, unless later filings replace it. The document is administrative in nature and does not present new financial results or major corporate transactions.

Immuron Limited, an Australian-based foreign private issuer, submitted a Form 6-K for September 2025 to provide U.S. investors with information also released on the Australian Securities Exchange. The company reports that it published two ASX announcements and attaches them as an exhibit.

The filing includes Exhibit 99.1, described as an Appendix 4G and Corporate Governance Statement. Immuron specifies that this Form 6-K and its exhibit are furnished, not filed, under the U.S. securities laws and will only be incorporated into other securities filings if explicitly referenced.